According to people familiar with the matter, pharmaceutical services company Parexel has drawn interest from suitors including AmerisourceBergen, Bloomberg reported.

A private equity consortium consisting of Cinven, Centerbridge Partners and GTCR is working on an offer, the people said, adding that private equity firm EQT is also vying to buy the firm on its own. Other bidders could include Veritas Capital, they added.

The people said Parexel has drawn interest from about 10 parties. Its owner, private equity firm Pamplona Capital Management, has narrowed down the bidders with a view to getting a deal done in the next few weeks, the sources added.

No final agreements have been reached, and talks could still fall apart, the people said, adding that the company could instead opt to proceed with an initial public offering.